CO5650246A2 - Derivados de indazolil(indolil)maleimida sustituidos como inhibidores de cinasa - Google Patents
Derivados de indazolil(indolil)maleimida sustituidos como inhibidores de cinasaInfo
- Publication number
- CO5650246A2 CO5650246A2 CO05127381A CO05127381A CO5650246A2 CO 5650246 A2 CO5650246 A2 CO 5650246A2 CO 05127381 A CO05127381 A CO 05127381A CO 05127381 A CO05127381 A CO 05127381A CO 5650246 A2 CO5650246 A2 CO 5650246A2
- Authority
- CO
- Colombia
- Prior art keywords
- sub
- inhibitors
- kinase
- indazolil
- maleimida
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
Abstract
1.- Los compuestos de fórmula (I)en donde R1 se selecciona a partir del grupo que consiste de: hidrógeno, alquilo de C1-8, alquenilo de C2-8, alquinilo de C2-8 y cicloalquilo de C3-8 {en donde alquilo, alquenilo, alquinilo y cicloalquilo de C3-8 están opcionalmente sustituidos con uno a dos sustituyentes independientemente seleccionados a partir del grupo que consiste de -O-alquilo de (C1-8), -O-alquilo de (C1-8)-OH, -O-alquilo de (C1-8)-O-alquilo de (C1-8), -O-alquilo de (C1-8)-NH2, -O-alquilo de (C1-8)-NH-alquilo de (C1-8), -O-alquilo de (C1-8)-N[alquilo de (C1-8)]2, -O-alquilo de (C1-8)-S-alquilo de (C1-8), -O-alquilo de (C1-8)-SO2-alquilo de (C1-8), -O-alquilo de (C1-8)-SO2-NH2, -O-alquilo de (C1-8)-SO2-NH-alquilo de (C1-8), -O-alquilo de (C1-8)-SO2-N[alquilo de (C1-8)]2, -O-C(O)H, -O-C(O)-alquilo de (C1-8), -O-C(O)-NH2, -O-C(O)-NH-alquilo de (C1-8), -O-C(O)-N[alquilo de (C1-8)]2, -O-alquilo de (C1-8)-C(O)H, -O-alquilo de (C1-8)-C(O)-alquilo de (C1-8), -O-alquilo de (C1-8)-CO2H, -O-alquilo de (C1-8)-C(O)-O-alquilo de (C1-8), O-alquilo de (C1-8)-C(O)-NH2, -O-alquilo de (C1-8)-C(O)-NH-alquilo de (C1-8), -O-alquilo de (C1-8)-C(O)-N[alquilo de (C1-8)]2, -C(O)H, -C(O)-alquilo de (C1-8), -CO2H, -C(O)-O-alquilo de (C1-8), -C(O)-NH2, -C(NH)-NH2, -C(O)-NH-alquilo de (C1-8), -C(O)-N[alquilo de (C1-8)]2, -SH, -S-alquilo de (C1-8), -S-alquilo de (C1-8)-S-alquilo de (C1-8), -S-alquilo de (C1-8)-O-alquilo de (C1-8), -S-alquilo de (C1-8)-O-alquilo de (C1-8)-OH, -S-alquilo de (C1-8)-O-alquilo de (C1-8)-NH2, -S-alquilo de (C1-8)-O-alquilo de (C1-8)-NH-alquilo de (C1-8), -S-alquilo de (C1-8)-O-alquilo de (C1-8)-N[alquilo de (C1-8)]2, -S-alquilo de (C1-8)-NH-alquilo de (C1-8), -SO2-alquilo de (C1-8), -SO2-NH2, -SO2-NH-alquilo de (C1-8), -SO2-N[alquilo de (C1-8)]2, amino (sustituido con dos sustituyentes independientemente seleccionados a partir del grupo que consiste de hidrógeno, alquilo de C1-8, alquenilo de C2-8, alquinilo de C2-8, -alquilo de (C1-8)-OH, -alquilo de (C1-8)-O-alquilo de (C1-8), -alquilo de (C1-8)-NH2, -alquilo de (C1-8)-NH-alquilo de (C1-8), -alquilo de (C1-8)-N-[alquilo de (C1-8)]2, -alquilo de (C1-8)-S-alquilo de (C1-8), -C(O)-alquilo de (C1-8), -C(O)O-alquilo de (C1-8), -C(O)-NH2, -C(O)-NH-alquilo de (C1-8), -C(O)-N[alquilo de (C1-8)]2, -SO2-alquilo de (C1-8), -SO2-NH2, -SO2-NH-alquilo de (C1-8),SO2-N[alquilo de (C1-8)]2, -C(N)-NH2, ...
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47851603P | 2003-06-13 | 2003-06-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5650246A2 true CO5650246A2 (es) | 2006-06-30 |
Family
ID=33551833
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO05127381A CO5650246A2 (es) | 2003-06-13 | 2005-12-19 | Derivados de indazolil(indolil)maleimida sustituidos como inhibidores de cinasa |
Country Status (22)
Country | Link |
---|---|
US (1) | US7439363B2 (es) |
EP (1) | EP1654255B1 (es) |
JP (1) | JP2007500748A (es) |
KR (1) | KR20060021890A (es) |
CN (1) | CN1832940A (es) |
AT (1) | ATE406365T1 (es) |
AU (1) | AU2004251178A1 (es) |
BR (1) | BRPI0411366A (es) |
CA (1) | CA2529353A1 (es) |
CO (1) | CO5650246A2 (es) |
CR (1) | CR8148A (es) |
DE (1) | DE602004016174D1 (es) |
EA (1) | EA200600032A1 (es) |
EC (1) | ECSP056222A (es) |
ES (1) | ES2311161T3 (es) |
HR (1) | HRP20050991A2 (es) |
IL (1) | IL172456A0 (es) |
IS (1) | IS8174A (es) |
NO (1) | NO20060145L (es) |
RS (1) | RS20050915A (es) |
WO (1) | WO2005000836A1 (es) |
ZA (1) | ZA200600294B (es) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA03005140A (es) * | 2000-12-08 | 2004-10-15 | Johnson & Johnson | Compuestos de pirrolina sustituidos con indazolilo como inhibidores de cinasa. |
AU2003225295A1 (en) * | 2002-05-08 | 2003-11-11 | Janssen Pharmaceutica N.V. | Substituted pyrroline kinase inhibitors |
DE60323749D1 (de) * | 2002-06-05 | 2008-11-06 | Janssen Pharmaceutica Nv | Substituierte pyrroline als kinase inhibitoren |
JP2006521386A (ja) * | 2003-03-27 | 2006-09-21 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | キナーゼ阻害剤である置換ピロリン |
WO2007025177A2 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
WO2007041195A2 (en) * | 2005-09-29 | 2007-04-12 | Janssen Pharmaceutica N.V. | Macroheterocylic compounds as kinase inhibitors |
WO2007047978A2 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
JP2009536669A (ja) | 2006-05-09 | 2009-10-15 | ブレインセルス,インコーポレイティド | アンジオテンシン調節による神経新生 |
KR101284836B1 (ko) | 2006-05-25 | 2013-07-10 | 삼성전자주식회사 | 이동통신시스템에서 자원 할당 맵 구성 방법 |
JP2010500300A (ja) | 2006-08-08 | 2010-01-07 | サノフィ−アベンティス | アリールアミノアリール−アルキル−置換イミダゾリジン−2,4−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用 |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
WO2008037266A1 (en) * | 2006-09-25 | 2008-04-03 | Universite Libre De Bruxelles | Inhibitors of conventional protein kinase c isozymes and use thereof for treating inflammatory diseases |
CN101558062A (zh) * | 2006-12-19 | 2009-10-14 | 诺瓦提斯公司 | 作为激酶抑制剂的吲哚基马来酰亚胺衍生物 |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
US8470841B2 (en) | 2008-07-09 | 2013-06-25 | Sanofi | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
CN102482312A (zh) | 2009-08-26 | 2012-05-30 | 赛诺菲 | 新颖的杂芳族氟代糖苷结晶水合物、含有这些化合物的药物和它们的用途 |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
ES2387359B1 (es) * | 2011-02-25 | 2013-08-01 | Consejo Superior De Investigaciones Científicas (Csic) | Inhibidores de GSK-3 útiles en enfermedades neurodegenerativas, inflamatorias, cáncer, diabetes y en procesos regenerativos |
WO2012120058A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8895547B2 (en) | 2011-03-08 | 2014-11-25 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2683702B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
EP2683698B1 (de) | 2011-03-08 | 2017-10-04 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
CN102344443A (zh) * | 2011-07-15 | 2012-02-08 | 南开大学 | 点击化学合成开环马来酰亚胺类化合物及其在治疗疾病中的应用 |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
CN103622964B (zh) * | 2013-12-04 | 2015-09-23 | 李强 | Trigolutesins A在治疗或预防急性心衰药物中的应用 |
US10220408B2 (en) * | 2016-09-12 | 2019-03-05 | The Boeing Company | Variable radius print head end effector |
CN108586432B (zh) * | 2018-05-31 | 2020-08-25 | 温州医科大学 | 一种3-(吲哚-5-基)-吲唑衍生物及其应用 |
EP3920885A1 (en) | 2019-02-08 | 2021-12-15 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ227850A (en) * | 1988-02-10 | 1991-11-26 | Hoffmann La Roche | Indole substituted pyrrole derivatives; preparatory process and medicaments for use against inflammatory immunological, bronchopulmonary or vascular disorders |
GB8904161D0 (en) * | 1989-02-23 | 1989-04-05 | Hoffmann La Roche | Substituted pyrroles |
US5624949A (en) * | 1993-12-07 | 1997-04-29 | Eli Lilly And Company | Protein kinase C inhibitors |
SE9603283D0 (sv) * | 1996-09-10 | 1996-09-10 | Astra Ab | New compounds |
CA2338866A1 (en) | 1998-07-30 | 2000-02-10 | Japan Tobacco Inc. | Disubstituted maleimide compound and pharmaceutical use thereof |
JP2002527419A (ja) | 1998-10-08 | 2002-08-27 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | Gsk−3阻害物質としてのピロール−2,5−ジオン類 |
MXPA03005140A (es) * | 2000-12-08 | 2004-10-15 | Johnson & Johnson | Compuestos de pirrolina sustituidos con indazolilo como inhibidores de cinasa. |
AU2003225295A1 (en) * | 2002-05-08 | 2003-11-11 | Janssen Pharmaceutica N.V. | Substituted pyrroline kinase inhibitors |
DE60323749D1 (de) * | 2002-06-05 | 2008-11-06 | Janssen Pharmaceutica Nv | Substituierte pyrroline als kinase inhibitoren |
CA2488602A1 (en) * | 2002-06-05 | 2003-12-18 | Janssen Pharmaceutica N.V. | Substituted pyrrolines as kinase inhibitors |
JP2006521386A (ja) * | 2003-03-27 | 2006-09-21 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | キナーゼ阻害剤である置換ピロリン |
-
2004
- 2004-06-01 RS YUP-2005/0915A patent/RS20050915A/sr unknown
- 2004-06-01 EP EP04754066A patent/EP1654255B1/en not_active Expired - Lifetime
- 2004-06-01 BR BRPI0411366-7A patent/BRPI0411366A/pt not_active IP Right Cessation
- 2004-06-01 CA CA002529353A patent/CA2529353A1/en not_active Abandoned
- 2004-06-01 DE DE602004016174T patent/DE602004016174D1/de not_active Expired - Fee Related
- 2004-06-01 KR KR1020057023946A patent/KR20060021890A/ko not_active Application Discontinuation
- 2004-06-01 EA EA200600032A patent/EA200600032A1/ru unknown
- 2004-06-01 JP JP2006533550A patent/JP2007500748A/ja not_active Withdrawn
- 2004-06-01 WO PCT/US2004/017375 patent/WO2005000836A1/en active Application Filing
- 2004-06-01 AT AT04754066T patent/ATE406365T1/de not_active IP Right Cessation
- 2004-06-01 ES ES04754066T patent/ES2311161T3/es not_active Expired - Lifetime
- 2004-06-01 AU AU2004251178A patent/AU2004251178A1/en not_active Abandoned
- 2004-06-01 US US10/858,212 patent/US7439363B2/en not_active Expired - Fee Related
- 2004-06-01 CN CNA200480022892XA patent/CN1832940A/zh active Pending
-
2005
- 2005-12-08 IL IL172456A patent/IL172456A0/en unknown
- 2005-12-09 IS IS8174A patent/IS8174A/is unknown
- 2005-12-13 EC EC2005006222A patent/ECSP056222A/es unknown
- 2005-12-13 HR HR20050991A patent/HRP20050991A2/xx not_active Application Discontinuation
- 2005-12-13 CR CR8148A patent/CR8148A/es not_active Application Discontinuation
- 2005-12-19 CO CO05127381A patent/CO5650246A2/es not_active Application Discontinuation
-
2006
- 2006-01-10 NO NO20060145A patent/NO20060145L/no not_active Application Discontinuation
- 2006-01-12 ZA ZA200600294A patent/ZA200600294B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
CA2529353A1 (en) | 2005-01-06 |
NO20060145L (no) | 2006-03-07 |
CN1832940A (zh) | 2006-09-13 |
CR8148A (es) | 2008-09-10 |
BRPI0411366A (pt) | 2006-07-25 |
DE602004016174D1 (de) | 2008-10-09 |
EP1654255B1 (en) | 2008-08-27 |
JP2007500748A (ja) | 2007-01-18 |
US20050004201A1 (en) | 2005-01-06 |
ES2311161T3 (es) | 2009-02-01 |
ATE406365T1 (de) | 2008-09-15 |
ECSP056222A (es) | 2006-04-19 |
EP1654255A1 (en) | 2006-05-10 |
ZA200600294B (en) | 2007-04-25 |
EA200600032A1 (ru) | 2006-06-30 |
HRP20050991A2 (en) | 2006-09-30 |
RS20050915A (sr) | 2008-04-04 |
WO2005000836A1 (en) | 2005-01-06 |
IS8174A (is) | 2005-12-09 |
US7439363B2 (en) | 2008-10-21 |
IL172456A0 (en) | 2006-04-10 |
AU2004251178A1 (en) | 2005-01-06 |
KR20060021890A (ko) | 2006-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5650246A2 (es) | Derivados de indazolil(indolil)maleimida sustituidos como inhibidores de cinasa | |
MY134783A (en) | Rho-kinase inhibitors | |
MY142915A (en) | Rho-kinase inhibitors | |
MA31574B1 (fr) | Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf | |
CY1107747T1 (el) | Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης | |
PT1362047E (pt) | Compostos de pirrolina substituidos com indazolilo como inibidores de cinase | |
WO2003103663A3 (en) | SUBSTITUTED PYRROLINES AS KINASE INHIBITORS | |
EA200601007A1 (ru) | 7-фенилалкилзамещённые 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза)полимеразы | |
YU84603A (sh) | Novi inhibitori tirozin kinaze | |
DE60318177D1 (de) | Rho-kinase inhibitoren | |
BRPI0506676A (pt) | piridazinona uréias como antagonistas de integrinas alfa4 | |
WO2009109991A3 (en) | Novel hydrazide containing tyrosine kinase inhibitors | |
EA200970936A1 (ru) | СОЕДИНЕНИЯ ПИРИДО[2,3-d]ПИРИМИДИН-7-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3K-АЛЬФА ДЛЯ ЛЕЧЕНИЯ РАКА | |
ATE403653T1 (de) | Pyridin-substituierte furanderivate als raf- kinase inhibitoren | |
HK1076107A1 (en) | Pyrrolidine derivatives as oxytocin antagonists | |
CO5680420A2 (es) | Compuestos de 6-amino-1h-indazol y 4-aminobenzenofurano como inhibidores de la fosfodiesterasa 4 | |
MX2023009045A (es) | Derivados novedosos de pirimidin-2-il sulfonamida. | |
DE602004005881D1 (de) | Substituierte pyrazinonverbindungen zur behandlung von entzündungen | |
EA200970497A1 (ru) | Производные пиррола, их получение и их применение в терапии | |
ATE419242T1 (de) | Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren | |
EA200601106A1 (ru) | Трициклические имидазопиридины для применения в качестве ингибиторов желудочной секреции | |
EA200100065A1 (ru) | Производные гидроксамовой кислоты как ингибиторы продуцирования cd23 человека и высвобождения tnf | |
SE0302824D0 (sv) | New use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Application withdrawn |